Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.

Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H, Spillner E, Klingner K, Schneider-Merck T, Binder M, Fiebig HH, Mertelsmann R, Trepel M.

Int J Cancer. 2012 Jul 15;131(2):E10-20. doi: 10.1002/ijc.26464. Epub 2011 Nov 19.

2.

A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.

Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC.

Clin Cancer Res. 2008 Jan 15;14(2):569-78. doi: 10.1158/1078-0432.CCR-07-1006.

3.

NF-ATc2 induces apoptosis in Burkitt's lymphoma cells through signaling via the B cell antigen receptor.

Kondo E, Harashima A, Takabatake T, Takahashi H, Matsuo Y, Yoshino T, Orita K, Akagi T.

Eur J Immunol. 2003 Jan;33(1):1-11.

4.

Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1.

Zhang L, Jiang Y, Zheng Y, Zeng Y, Yang Z, Huang G, Liu D, Gao M, Shen X, Wu G, Yan X, He F.

Leukemia. 2011 Feb;25(2):331-40. doi: 10.1038/leu.2010.261. Epub 2010 Nov 19.

5.

Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.

Perez-Chacon G, de Los Rios C, Zapata JM.

Pharmacol Res. 2014 Nov;89:46-56. doi: 10.1016/j.phrs.2014.08.005. Epub 2014 Aug 30.

PMID:
25180456
7.

Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.

Mori N, Ishikawa C, Senba M, Kimura M, Okano Y.

Biochem Pharmacol. 2011 May 1;81(9):1106-15. doi: 10.1016/j.bcp.2011.02.010. Epub 2011 Mar 1. Erratum in: Biochem Pharmacol. 2011 Nov 1;82(9):1252.

PMID:
21371446
8.

Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.

Lan K, Murakami M, Bajaj B, Kaul R, He Z, Gan R, Feldman M, Robertson ES.

Cancer Biol Ther. 2009 Nov;8(22):2136-43. Epub 2009 Nov 7.

PMID:
19783901
9.

Costimulatory signals distinctively affect CD20- and B-cell-antigen-receptor-mediated apoptosis in Burkitt's lymphoma/leukemia cells.

Mimori K, Kiyokawa N, Taguchi T, Suzuki T, Sekino T, Nakajima H, Saito M, Katagiri YU, Isoyama K, Yamada K, Matsuo Y, Fujimoto J.

Leukemia. 2003 Jun;17(6):1164-74.

PMID:
12764385
10.

Improved access to CD20 following B cell receptor cross-linking at Burkitt's lymphoma cell surfaces.

Holder MJ, Chamba A, Hardie DL, Deans JP, Gordon J.

Leuk Res. 2004 Nov;28(11):1197-202.

PMID:
15380345
11.

The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.

Tong X, Zhang X, Fan J, Tong Y, Li S, Jin J, Yao H.

Cancer Biol Ther. 2013 Apr;14(4):370-7. doi: 10.4161/cbt.23718. Epub 2013 Jan 29.

12.

Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.

Schnell R, Katouzi AA, Linnartz C, Schoen G, Drillich S, Hansmann ML, Schiefer D, Barth S, Zangemeister-Wittke U, Stahel RA, Diehl V, Engert A.

Int J Cancer. 1996 May 16;66(4):526-31.

13.

Curcumin induces apoptosis and inhibits growth of human Burkitt's lymphoma in xenograft mouse model.

Li ZX, Ouyang KQ, Jiang X, Wang D, Hu Y.

Mol Cells. 2009 Mar 31;27(3):283-9. doi: 10.1007/s10059-009-0036-9. Epub 2009 Mar 19.

14.

A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.

Tsai LK, Pop LM, Liu X, Vitetta ES.

Toxins (Basel). 2011 Apr;3(4):409-19. doi: 10.3390/toxins3040409. Epub 2011 Apr 6.

15.

In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder.

Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, De Laurentiis A, Luberto L, Pontoriero M, Pisano A, Vecchio E, Fierro O, Panico MR, Larobina M, Gargiulo S, Costa N, Dal Piaz F, Schiavone M, Arra C, Giudice A, Palma G, Barbieri A, Quinto I, Scala G.

Blood. 2010 Jul 15;116(2):226-38. doi: 10.1182/blood-2009-11-253617. Epub 2010 Apr 2.

16.

Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas.

Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC.

Mol Cancer Ther. 2005 Dec;4(12):2037-44.

17.
18.

Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo.

Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH.

Cancer Biol Ther. 2005 May;4(5):571-82. Epub 2005 May 5.

PMID:
15846081
19.

A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.

Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, Pastan I.

J Immunother. 2010 Apr;33(3):297-304. doi: 10.1097/CJI.0b013e3181cd1164.

PMID:
20445350
20.

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.

Breton CS, Nahimana A, Aubry D, Macoin J, Moretti P, Bertschinger M, Hou S, Duchosal MA, Back J.

J Hematol Oncol. 2014 Apr 14;7:33. doi: 10.1186/1756-8722-7-33.

Items per page

Supplemental Content

Write to the Help Desk